Restricted optimality for phase I clinical trials
Restricted optimality for phase I clinical trials
We derive locally c-and D-optimal designs for maximum likelihood estimation of the maximum tolerated dose from a phase I clinical trial.We assume that the response function can be modeled by a distribution function and there is an ethical constraint on the dose space, as patients should not be assigned to …